Drugs / DS9051b
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07189403 | Nov 2025 → Mar 2028 expected | adrenal cortex carcinoma, castration-resistant prostate carcinoma | Daiichi Sankyo | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DS9051b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07189403 ↗ |
| Route | Oral | “Administered orally” NCT07189403 ↗ |